Literature DB >> 16316750

The wide diversity and complexity of peptides bound to class II MHC molecules.

Anish Suri1, Scott B Lovitch, Emil R Unanue.   

Abstract

The identification and quantitation of peptides selected by class II MHC molecules during natural processing of proteins is of key importance in understanding the repertoire and distribution of T cells. The examination of peptides selected by class II MHC molecules has depended greatly on mass spectrometry, a powerful technique that identifies and sequences peptides in complex mixtures with great sensitivity and precision. Such analysis has resulted in the identification of several factors, including the repertoire of peptides selected by MHC molecules during natural processing of proteins, motifs important for selection of processed peptides, conformational isomers of peptide-MHC complexes, and post-translational changes to the peptides.

Mesh:

Substances:

Year:  2005        PMID: 16316750     DOI: 10.1016/j.coi.2005.11.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  25 in total

Review 1.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

2.  Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II.

Authors:  Dirk Homann; Hanna Lewicki; David Brooks; Jens Eberlein; Valerie Mallet-Designé; Luc Teyton; Michael B A Oldstone
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

3.  Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin.

Authors:  James S Testa; Geraud S Apcher; Joseph D Comber; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

4.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

5.  Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells.

Authors:  Leonia Bozzacco; Haiqiang Yu; Henry A Zebroski; Jörn Dengjel; Haiteng Deng; Svetlana Mojsov; Ralph M Steinman
Journal:  J Proteome Res       Date:  2011-10-14       Impact factor: 4.466

6.  Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis.

Authors:  Toolika Singh; Michaela Fakiola; Joyce Oommen; Akhil Pratap Singh; Abhishek K Singh; Noel Smith; Jaya Chakravarty; Shyam Sundar; Jenefer M Blackwell
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

7.  Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization.

Authors:  Linda K Myers; David L Cullins; Jeoung-Eun Park; Ae-Kyung Yi; David D Brand; Edward F Rosloniec; John M Stuart; Andrew H Kang
Journal:  Clin Immunol       Date:  2015-05-14       Impact factor: 3.969

Review 8.  Donor-unrestricted T cells in the human CD1 system.

Authors:  Shouxiong Huang; D Branch Moody
Journal:  Immunogenetics       Date:  2016-08-09       Impact factor: 2.846

Review 9.  Present Yourself! By MHC Class I and MHC Class II Molecules.

Authors:  Kenneth L Rock; Eric Reits; Jacques Neefjes
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

10.  Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Authors:  Olesya Chornoguz; Alexei Gapeev; Michael C O'Neill; Suzanne Ostrand-Rosenberg
Journal:  Mol Cell Proteomics       Date:  2012-08-31       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.